World Pharma Today

  Noah Nasser, CEO of  datma Most pharmaceutical companies have already invested heavily in real-world data (RWD). These internal datasets, often curated over years, serve as the foundation for ongoing research and analysis. They often represent significant investment in time, budget, and coordination across internal teams and systems. But even robust internal datasets can fall short when new analytical needs or questions arise, particularly in the context of targeted therapies where biomarker specific insights are essential.  When a stakeholder asks a question about a subpopulation defined by a biomarker, mutation type, or clinical context, the existing dataset may not contain the patients needed to answer it. The missing data might be subtle, such as biomarker status or specific genomic features, but they are often essential. This doesn’t mean the internal dataset is flawed, it reflects the evolving nature of oncology and the reality that new questions often demand new ...

  Sanome’s MEMORI becomes the first UK‑built, Certified Class IIb Software-as-a-Medical Device for real-time infection prediction, ahead of NHS rollout and FDA approval. AI tool that spots hospital infections up to 72 hours early, newly backed by former health minister Lord Bethell, Prof Carole Longson and Dr Arrash Yassaee Sanome’s MEMORI becomes the first UK-developed AI medical device that predicts and detects infections earlier, to achieve Class IIb Medical Device CE certification and MHRA approval The technology delivers real-time alerts to clinical teams with no disruption, helping ease pressure on overburdened hospitals, supporting the new NHS 10-Year Plan’s focus on prevention and early intervention Sanome, a company building Clinical Decision Support tools to detect emerging health risks, has secured Class IIb CE certification and MHRA approval for MEMORI – an AI-enabled warning system for the early prediction/prevention of healthcare‑associated infections (HAIs) – at the ...

  Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company. In a significant step toward strengthening India’s efforts in nutrition and metabolism research, Agilent Technologies and the Tata Institute of Fundamental Research (TIFR), Hyderabad have announced a strategic collaboration to support ARUMDA (Advanced Research Unit on Metabolism, Development, and Aging). This partnership brings together Agilent’s global expertise in analytical science with TIFR’s research endeavors to address the growing burden of non-communicable diseases (NCDs) and malnutrition in the country. A key outcome of this collaboration is the launch of the Agilent–TIFR Center of Translational Research in Hyderabad. The center will play a pivotal role in supporting the Advanced Research Unit on Metabolism, Development & Aging (ARUMDA)—one of India’s most ambitious government-supported initiatives in human health. ARUM...